T cell revival through PD-1: Clues for cancer immunotherapy

August 2, 2016, Emory University
Spleen of LCMV-infected mouse. The population of PD-1-responsive T cells is CD8+ and TCF1+ and thus appears as yellow. Credit: From Im et al. Nature (2016)

Cancer immunotherapy drugs that block the inhibitory PD-1 pathway have shown success in clinical trials and are now FDA-approved for melanoma, lung cancer and bladder cancer. Yet many patients' tumors do not respond to these drugs.

Scientists from Emory Vaccine Center have now shown what molecular features distinguish the subset of T cells that wake up when re-energized by PD-1-blocking agents.

The researchers expect that their findings will be valuable for optimizing treatment with PD-1-targeting drugs. The experiments were performed in mice with , the system in which T cell exhaustion and PD-1's immune-braking function were first discovered.

The results are scheduled for online publication in Nature at 11 am Eastern time on Tuesday, August 2.

PD-1-blocking agents such as nivolumab, pembrolizumab and atezolizumab are part of a class of drugs known as checkpoint inhibitors, and many cancer researchers are now trying to figure out how to enhance their activity by combining them with other types of drugs.

"If we know more about the markers on the T cells that expand after PD-1's inhibition is removed, that could facilitate the rational design of combination therapies," says senior author Rafi Ahmed, PhD, director of Emory Vaccine Center and a Georgia Research Alliance Eminent Scholar.

The first author of the Nature paper is postdoctoral fellow Sejin Im, PhD. Collaborators from NIAID (National Institute of Allergy and Infectious Diseases), University of Iowa, Harvard Medical School, Dana Farber Cancer Institute and University of São Paolo, Brazil contributed to the paper.

More than a decade ago, Ahmed and colleagues had shown that the immune systems of mice with chronic viral infections were full of inactive, or "exhausted" antiviral T cells. These cells displayed high levels of PD-1, and antiviral activity could be revived if PD-1's interactions with its counterpart on other cells (PD-L1) were blocked.

In the current paper, the authors demonstrate that the exhausted antiviral T cells can be divided into two groups. One group undergoes a proliferative burst when virus-infected mice are given PD-1-blocking antibodies, and the other group lacks the capacity to proliferate.

Even before PD-1-blocking antibodies were introduced, the expandable group of virus-specific T cells was dividing at a slow rate. These cells were only in the T cell zones of lymphoid organs (lymph nodes and spleen), not circulating throughout the body. After PD-1 is blocked, these cells divide and differentiate into effector-like cells that migrate to infected tissues.

"If you imagine chronic viral infection - or cancer—as a war, the expandable T cells are not in the intense part of the battle," Ahmed says. "But they are somewhat engaged. It's like they're waiting in a shelter, ready to respond."

The researchers also showed that a gene called TCF1 was important for the generation and maintenance of the PD-1-responsive T cells in mice. Inside and outside, the PD-1-responsive cells had molecular characteristics that resembled memory T cells or stem-like cells, while the non-responsive T cells were more terminally differentiated.

The authors catalogued several co-stimulatory molecules and receptors present on the surfaces of the PD-1-responsive T cells, which possibly could be targets for drugs.

In collaboration with researchers at Winship Cancer Institute of Emory University, Ahmed's laboratory is looking for with similar characteristics in cancer patients. It is possible that this group of revivable T may be found in contact with the tumor, or perhaps more likely, in lymph nodes nearby, Ahmed says.

Explore further: Immunotherapy agent can disrupt viral reservoir in SIV-infected monkeys

Related Stories

Immunotherapy agent can disrupt viral reservoir in SIV-infected monkeys

February 25, 2016
An immune-enhancing treatment can push SIV (simian immunodeficiency virus) out of its hideouts in infected monkeys that have the virus controlled with drugs, scientists at Yerkes National Primate Research Center, Emory University ...

Study reveals protein that dials immune responses up and down

May 26, 2016
Research led by scientists at the Sanford Burnham Prebys Medical Discovery Institute (SBP) has identified a new regulator of immune responses. The study, published recently in Immunity, sheds new light on why T cells fail ...

Immune 'traffic jam' from viral infection interferes with therapeutic antibodies

February 12, 2015
Several drugs now used to treat cancer and autoimmune diseases are actually repurposed tools derived from the immune system. One of the ways these "therapeutic antibodies" work is to grab onto malignant or inflammatory cells ...

'Pep talk' can revive immune cells exhausted by chronic viral infection

December 13, 2011
Chronic infections by viruses such as HIV or hepatitis C eventually take hold because they wear the immune system out, a phenomenon immunologists describe as exhaustion.

Vaccine blackjack: IL-21 critical to fight against viral infections

May 23, 2013
(Medical Xpress)—Scientists at Emory Vaccine Center have shown that an immune regulatory molecule called IL-21 is needed for long-lasting antibody responses in mice against viral infections.

Recommended for you

Non-coding DNA reveals a route by which advanced prostate cancer resists treatment

June 15, 2018
Two research teams converge on epigenetic switches that feed treatment-resistant metastatic prostate tumors. This research highlights the value of exploring gene regulation and large-scale structural changes in the cancer ...

Researchers peer inside cells to spy on cancer's on-off switch

June 15, 2018
Forty years after researchers first discovered it in fruit flies, a once-obscure cluster of proteins called PRC2 has become a key target for new cancer-fighting drugs, due to its tendency—when mutated—to bind to and silence ...

PIM-2 protein kinase regulates T-cell activity differently than PIM-1 or PIM-3 isoform

June 15, 2018
The PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity, while PIM-1 and PIM-3 are positive regulators, report Medical University of South Carolina (MUSC) investigators in an article ...

Gene testing could identify men with prostate cancer who may benefit from immunotherapy

June 14, 2018
Scientists have identified a pattern of genetic changes that could pick out men with advanced prostate cancer who are likely to benefit from immunotherapy.

Without 'yoga and chardonnay' leukemia stem cells are stressed to death

June 14, 2018
Change is stressful. The change that a healthy blood stem cell undergoes to become a leukemia stem cell (LSC) is no exception—think of healthy blood stem cells as young professionals and the transformation into an LSC as ...

Statins found to enhance efficacy of chemotherapy drug in blood cancers

June 14, 2018
A team of researchers with members affiliated with several institutions in the U.S. has found that some statins could enhance the efficacy of a chemotherapy drug used to fight blood cancers in mouse models. In their paper ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.